Re-thinking the prostate cancer diagnostic pathway: the acceptability of the Rapid Access Prostate Imaging and Diagnosis (RAPID) pathway
BAUS ePoster online library. Bertoncelli Tanaka M. Jun 25, 2019; 259472; P10-4 Disclosure(s): I have no actual or potential conflict ofinterest in relation to this program/presentation
Mariana Bertoncelli Tanaka
Mariana Bertoncelli Tanaka
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
Introduction and Objective
Our new 'one-stop' Rapid Access Prostate Imaging and Diagnosis (RAPID) pathway, across three hospitals in our region, streamlines the traditional pathway. We aimed to determine patient acceptability of the combination of same-day mpMRI, clinical review and transperineal prostate biopsy or discharge.

METHODS

Consecutive patients on the RAPID pathway were approached for detailed feedback via standardised questionnaires through an independent third party to minimize data collection bias. Patients were approached on only certain days.

Results
Of 837 patients within RAPID (April/2017 to September/2018), 62 completed the questionnaire. The mean time from referral to mpMRI +/- biopsy was 10.3 (7 to 13) days. 83% (52/62) thought that time from GP referral to first appointment was sooner than expected. 66% (41/62) of patients stated that time from referral to final diagnosis was shorter than expected. 12.9% (8/62) would have preferred the mpMRI and biopsy on different days. The overall patient's experience was rated as very good by 54/62 of patients, fairly good in 7/62 of cases and only one report as neutral experience. There was no negative experience reported. All patients stated that there was a good interaction between primary and specialist care whilst in the pathway.

Conclusions
The RAPID pathway provides a fast-access, robust, one-stop approach to prostate cancer diagnostics. Patient acceptability is high. As a result of our clinical and patient acceptability, further roll-out to 3-4 more centres is underway.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings